The chopra foundation and mindmed enter into letter of intent to partner on the future of psychedelic medicines & mental wellbeing

New york, may 18, 2021 /prnewswire/ --  mind medicine (mindmed) inc. (nasdaq: mnmd) (neo: mmed) (de: mmq) ("mindmed" or the "company"), a leading clinical stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with the chopra foundation to educate and build public awareness around the use of psychedelic medicines to treat mental illness, remove outdated stigmas, and ultimately research mental wellbeing approaches that can be used in psychedelic related psychotherapy. the two organizations plan to design and conduct research together surrounding altered states of consciousness, psychedelic psychotherapy, and their overall impact on mental wellbeing.
MNMD Ratings Summary
MNMD Quant Ranking